1. Reports of a rare type of blood clot following vaccination with both Johnson & Johnson and AstraZeneca’s COVID-19 vaccines have emerged in recent weeks, and U.S. health regulators April 13 recommended that the use of the Johnson & Johnson vaccine be halted. Here’s what you should know.
2. Pfizer CEO Albert Bourla, PhD, said April 13 the drugmaker can deliver 10 percent more COVID-19 vaccine doses than agreed upon to the U.S. by the end of May, a total of 220 million doses.
3. Moderna said April 13 that its vaccine was more than 90 percent effective six months after the second dose and more than 95 percent effective against severe cases of COVID-19, according to a phase 3 study.
4. Pfizer and BioNTech have requested that the FDA authorize their COVID-19 vaccine for use in people as young as 12 years old.
More articles on surgery centers:
Hospitals aren’t rushing to buy ASCs; here’s what’s happening instead
Hospital sues gastroenterologists attempting to exit contracts: 5 details
7 reimbursement updates for ASCs, key insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.